By Aditya Samal (Reuters) -Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a panel meeting.
Latest posts by Crypto Editor (see all)
- FP Markets Webinar for January 31: Explore TradingView with FP Markets Market Analyst Aaron Hill - January 18, 2024
- Crude Oil Price Forecast – Crude Oil Continues to Bounce Around - January 18, 2024
- AUD/USD Forecast – Australian Dollar Continues to Test Support - January 18, 2024